多国实用性随机临床试验SafeBoosC-III中使用的替代知情同意方法
本研究为SafeBoosC-III试验的描述性辅助研究,向70名主要研究者发放问卷,评估各中心在极早产儿出生后6小时内开始、持续3天的脑氧饱和度监测试验中采用的知情同意方法。61个中心提供数据,43个中心仅使用事先知情同意,7个仅使用延迟同意,无中心仅使用选择退出法,共记录23项关切。
要点
- 61个中心中43个仅用事先知情同意,7个仅用延迟同意,无中心仅用选择退出法。
- 5个中心使用事先和延迟同意,5个使用全部三种方法,1个使用延迟和选择退出。
- 6个中心申请使用选择退出法被当地伦理委员会拒绝,1个申请延迟同意被拒。
核心结论
- 选择退出法虽被方案允许,但仅少数研究者选用,部分伦理委员会不接受其使用,可能需要临床研究界推动以发挥其潜力。
研究设计与样本
- 多国实用性随机临床试验SafeBoosC-III的描述性辅助研究,邀请全部70名主要研究者填写问卷。
主要发现
- 61个中心提供数据:43个中心仅用事先知情同意,7个仅用延迟同意,无中心仅用选择退出法。
- 5个中心使用事先和延迟同意,5个使用事先、延迟和选择退出全部三种方法,1个使用延迟和选择退出。
- 6个中心申请使用选择退出法被当地研究伦理委员会拒绝,1个中心申请使用延迟同意被拒。
- 试验执行期间仅记录23项关切。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The process of obtaining prior informed consent for experimental treatment does not fit well into the clinical reality of acute and intensive care. The therapeutic window of interventions is often short, which may reduce the validity of the consent and the rate of enrolled participants, to delay trial completion and reduce the external validity of the results. Deferred consent and 'opt-out' are alternative consent methods. The SafeBoosC-III trial was a randomised clinical trial investigating the benefits and harms of cerebral oximetry monitoring in extremely preterm infants during the first 3 days after birth, starting within the first 6 h after birth. Prior, deferred and opt-out consent were all allowed by protocol. This study aimed to evaluate the use of different consent methods in the SafeBoosC-III trial, Furthermore, we aimed to describe and analyse concerns or complaints that arose during the first 6 months of trial conduct. METHODS: All 70 principal investigators were invited to join this descriptive ancillary study. Each principal investigator received a questionnaire on the use of consent methods in their centre during the SafeBoosC-III trial, including the possibility to describe any concerns related to the consent methods used during the first 6 months of the trial, as raised by the parents or the clinical staff. RESULTS: Data from 61 centres were available. In 43 centres, only prior informed consent was used: in seven, only deferred consent. No centres used the opt-out method only, but five centres used prior and deferred, five used prior, deferred and opt-out (all possibilities) and one used both deferred and opt-out. Six centres applied to use the opt-out method by their local research ethics committee but were denied using it. One centre applied to use deferred consent but was denied. There were only 23 registered concerns during the execution of the trial. CONCLUSIONS: Consent by opt-out was allowed by the protocol in this multinational trial but only a few investigators opted for it and some research ethics boards did not accept its use. It is likely to need promotion by the clinical research community to unfold its potential.
引用
- Vestager ML, Hansen ML, Greisen G, et al. Alternative consent methods used in the multinational, pragmatic, randomised clinical trial SafeBoosC-III. Trials. 2024. PMID: 38575977. doi:10.1186/s13063-024-08074-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。